Victoza for weight loss: what TikTok gets wrong about liraglutide
Quick answer
The creator is using Victoza (liraglutide), a daily GLP-1 receptor agonist FDA-approved for type 2 diabetes, and documenting early appetite suppression consistent with the drug's known hypothalamic mechanism. She uses a 4mm needle tip for subcutaneous abdominal injection and mentions alternating injection sides, both of which align with current injection technique guidance. The video does not address her diagnosis, prescribed dose, or supervising provider, and conflates Victoza's daily dosing schedule with the weekly schedule of semaglutide.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team· This is not a transcript. It is our independent review of the video above.
What did @twinkiemamis actually say?
The creator documented herself doing a weekly Victoza (liraglutide) injection, noting she had just eaten "majority of the apple" and wasn't very hungry. She mentioned this was week two of her journey, referenced a 4mm needle tip, and admitted significant anxiety around injections. She also said her sister does a once-weekly shot, which she envied.
To be clear: this video is not a medical tutorial. It is a personal experience share with a lot of profanity and relatable nervousness. The creator does not make sweeping clinical claims. What she does do is normalize self-injection of a GLP-1 medication, reference dosing frequency, and frame reduced appetite as a positive sign of the drug working. Each of those points deserves some scrutiny.
Does the science back this up?
On reduced appetite after starting liraglutide, yes, the evidence is solid. The mechanism is well-established and the clinical data is not ambiguous here.
Liraglutide works primarily by activating GLP-1 receptors in the hypothalamus and brainstem, slowing gastric emptying and suppressing appetite signals. The SCALE Obesity and Prediabetes trial (Pi-Sunyer et al., 2015, NEJM) showed liraglutide 3.0 mg daily produced an average 8.4% body weight loss over 56 weeks versus 2.8% with placebo, largely attributed to reduced caloric intake driven by appetite suppression. The creator saying she "ate an apple" and wasn't hungry is consistent with what liraglutide does pharmacologically in early weeks of treatment.
However, Victoza is FDA-approved for type 2 diabetes management, not weight loss. The 3.0 mg dose branded as Saxenda is the approved weight-loss formulation. Using Victoza off-label for weight loss is not uncommon, but it is a clinical distinction that matters and the video does not address it at all.
What did they get wrong (or right)?
The creator said her sister does her injection "once a week," which she frames as preferable. This is almost certainly a reference to semaglutide (Ozempic or Wegovy), not liraglutide. Victoza is dosed daily, not weekly. This is not a minor detail. Confusing daily and weekly GLP-1 dosing schedules is a real medication safety issue.
Accidental weekly dosing of a daily drug like liraglutide could mean missed therapeutic effect; accidental daily dosing of a weekly drug like semaglutide could mean serious overdose risk including severe nausea, vomiting, and hypoglycemia in diabetic patients. The FDA has documented GLP-1 dosing errors in its MedWatch system, and a 2023 safety communication from the Institute for Safe Medication Practices specifically flagged confusion between daily and weekly GLP-1 agents as an emerging harm pattern.
What she got right: the 4mm needle tip she references is consistent with current clinical guidance. A 2015 consensus statement from the Forum for Injection Technique recommended 4mm pen needles for subcutaneous injection in most adults regardless of BMI, citing equivalent glycemic outcomes with lower injection-site pain and reduced risk of intramuscular injection.
What should you actually know?
If you are watching this video and thinking about starting a GLP-1 medication, here is what the creator did not cover.
- Daily vs. weekly matters enormously. Liraglutide (Victoza, Saxenda) is injected daily. Semaglutide (Ozempic, Wegovy) and dulaglutide (Trulicity) are weekly. These are not interchangeable schedules, and mixing them up has documented safety consequences.
- Injection site rotation is not optional. The creator mentions alternating sides, which is correct. Repeated injection into the same site causes lipohypertrophy, a localized fat buildup that impairs drug absorption. A 2016 study by Blanco et al. in Diabetes Care found lipohypertrophy in 41% of insulin users who did not rotate sites, with measurable impact on glycemic control. The same principle applies to GLP-1 pens.
- Reduced appetite is expected, not a reason to skip meals entirely. Eating "majority of an apple" as a meal is not a medically supervised eating pattern. GLP-1-associated nausea and appetite suppression can lead to inadequate protein and micronutrient intake, particularly in rapid weight loss contexts.
- Victoza is not FDA-approved for weight loss. Off-label use happens and is legal, but it means your prescriber is making a judgment call outside the approved indication. That is a conversation to have explicitly with your provider, not something to infer from a TikTok.
The bottom line
This video is not dangerous misinformation. It is an honest, unpolished personal account that happens to contain one significant factual error about dosing frequency and several gaps in clinical context. The creator's anxiety about needles is relatable and her appetite suppression experience is pharmacologically consistent. But 34,000 viewers watching someone casually confuse daily and weekly GLP-1 schedules is a genuine public health concern, even if unintentional.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Access rules depend on the compound and patient situation
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 7 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For Victoza for weight loss: what TikTok gets wrong about liraglutide, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Primary STEP 1 trial source for semaglutide weight-management efficacy and adverse-event context.
PubMed
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance
Used for maintenance, discontinuation, and weight-regain discussions after semaglutide response.
PubMed
Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference
A broad meta-analysis anchor for GLP-1 weight-loss effect and class-level comparisons.
PubMed
Discontinuing glucagon-like peptide-1 receptor agonists and body habitus
Used for pages discussing stopping therapy, weight regain, and long-term planning.
PubMed
Video claim decision path
Turn the claim into a safer next question
Direct answer
Victoza for weight loss: what TikTok gets wrong about liraglutide should be treated as a claim to verify, then compared with evidence, safety context, and a provider review path.
Evidence check
Social clips are useful prompts, but they rarely show the full evidence base, contraindications, or dosing context.
Safety check
A viral claim can miss patient-specific risks, medication interactions, legal access, and source quality.
Next step
Use the health tools and supporting evidence to prepare questions for your clinician.
Helpful context before the funnel
Claim verdict
The useful answer behind this video
Claim being checked
The creator is using Victoza (liraglutide), a daily GLP-1 receptor agonist FDA-approved for type 2 diabetes, and documenting early appetite suppression consistent with the drug's known hypothalamic mechanism.
FormBlends verdict
The creator is using Victoza (liraglutide), a daily GLP-1 receptor agonist FDA-approved for type 2 diabetes, and documenting early appetite suppression consistent with the drug's known hypothalamic mechanism. She uses a 4mm needle tip for subcutaneous abdominal injection and mentions alternating injection sides, both of which align with current injection technique guidance. The video does not address her diagnosis, prescribed dose, or supervising provider, and conflates Victoza's daily dosing schedule with the weekly schedule of semaglutide.
Patient-safe next step
Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- The creator is using Victoza (liraglutide), a daily GLP-1 receptor agonist FDA-approved for type 2 diabetes, and documenting early appetite suppression consistent with the drug's known hypothalamic mechanism. She uses a 4mm needle tip for subcutaneous abdominal injection and mentions alternating injection sides, both of which align with current injection technique guidance. The video does not address her diagnosis, prescribed dose, or supervising provider, and conflates Victoza's daily dosing schedule with the weekly schedule of semaglutide.
- Liraglutide (Victoza) is a daily injection, not weekly. The SCALE trial (Pi-Sunyer et al., 2015, NEJM) studied daily dosing; confusing it with weekly semaglutide schedules is a documented medication error risk per ISMP 2023.
- Victoza is FDA-approved for type 2 diabetes. Saxenda, also liraglutide but at 3.0 mg, holds the FDA weight management approval. These are not the same clinical product.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compound access, legal status, and product quality still need a separate safety check.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.
Start provider reviewWhat You'll Learn
- Liraglutide (Victoza) is a daily injection, not weekly. The SCALE trial (Pi-Sunyer et al., 2015, NEJM) studied daily dosing; confusing it with weekly semaglutide schedules is a documented medication error risk per ISMP 2023.
- Victoza is FDA-approved for type 2 diabetes. Saxenda, also liraglutide but at 3.0 mg, holds the FDA weight management approval. These are not the same clinical product.
- Appetite suppression this early in treatment is pharmacologically expected. GLP-1 receptors in the hypothalamus and brainstem modulate satiety signals, which is why 'not really hungry' after an apple is a real drug effect, not a placebo response.
- 4mm pen needles are evidence-based. The 2015 Forum for Injection Technique consensus found no clinical advantage to longer needles for subcutaneous GLP-1 or insulin delivery in most adults.
- Injection site rotation prevents lipohypertrophy, a fat tissue change that reduces drug absorption. Blanco et al. (2016, Diabetes Care) found 41% of injection therapy users who skipped rotation developed this complication.
- Eating 'majority of an apple' as a meal is not a supervised nutrition plan. GLP-1-driven appetite suppression can mask inadequate protein and micronutrient intake, which becomes clinically relevant over weeks of use.
- Off-label prescribing is legal but requires an explicit conversation with your provider. Inferring your treatment plan from TikTok content, even well-intentioned content, is not a substitute for that conversation.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
TwinkieMami’s · TikTok creator
34.2K views on this video
Come do my shot with me #victoza #victozaweightloss #weightlossinjection
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by TwinkieMami’s, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.